$3.48+0.16 (+4.82%)
News25/Ratings1
Price$3.48-1.28 (-26.89%)
2026-01-212026-04-24
News · 26 weeks38-100%
2025-11-022026-04-26
Mix1990d
- SEC Filings7(37%)
- Insider6(32%)
- Other5(26%)
- Leadership1(5%)
Latest news
25 items- INSIDERSEC Form 4 filed by Burnam Bradley Evan4 - Turn Therapeutics Inc. (0002023016) (Issuer)
- INSIDERSEC Form 4 filed by Golden Arthur F4 - Turn Therapeutics Inc. (0002023016) (Issuer)
- INSIDERSEC Form 4 filed by Burnam Bradley Evan4 - Turn Therapeutics Inc. (0002023016) (Issuer)
- INSIDERSEC Form 4 filed by Chaudhary Zuraiz4 - Turn Therapeutics Inc. (0002023016) (Issuer)
- SECSEC Form EFFECT filed by Turn Therapeutics Inc.EFFECT - Turn Therapeutics Inc. (0002023016) (Filer)
- SECSEC Form EFFECT filed by Turn Therapeutics Inc.EFFECT - Turn Therapeutics Inc. (0002023016) (Filer)
- SECSEC Form POS AM filed by Turn Therapeutics Inc.POS AM - Turn Therapeutics Inc. (0002023016) (Filer)
- SECSEC Form POS AM filed by Turn Therapeutics Inc.POS AM - Turn Therapeutics Inc. (0002023016) (Filer)
- SECSEC Form 10-K filed by Turn Therapeutics Inc.10-K - Turn Therapeutics Inc. (0002023016) (Filer)
- SECTurn Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition8-K - Turn Therapeutics Inc. (0002023016) (Filer)
- PRTurn Therapeutics Reports Full Year 2025 Financial Results and Provides Corporate UpdatesPhase 2 Trial for GX-03 in Moderate-Severe Atopic Dermatitis on Track, Topline Results Expected Mid-2026 Secured up to $25 Million in Growth Capital from Avenue Capital Group Strengthened Leadership Team via Appointments of Dr. Robert Redfield and Martin Dewhurst Turn Therapeutics Inc. (NASDAQ:TTRX), a clinical-stage biotechnology company developing targeted inflammatory and immunology therapies for dermatologic conditions, today reported financial results for the year ended December 31, 2025, and provided corporate updates. "Our first months as a public company have been highly productive, with strong progress across our clinical, financial, and strategic priorities," said Bradley
- SECTurn Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Unregistered Sales of Equity Securities, Regulation FD Disclosure, Financial Statements and Exhibits8-K - Turn Therapeutics Inc. (0002023016) (Filer)
- PRTurn Therapeutics Secures Up to $25 Million in Financing From Avenue Capital GroupFinancing Extends Runway and Supports Continued Advancement of Atopic Dermatitis (Eczema) and Onychomycosis (Nail Fungus) Programs Turn Therapeutics, Inc. (NASDAQ:TTRX), a clinical-stage dermatology company developing novel therapies for inflammatory skin diseases, today announced it has entered into a growth capital loan facility with Avenue Venture Opportunities Fund II, L.P., a fund of Avenue Capital Group, for up to $25 million. The facility includes an initial $7 million tranche funded at closing, with up to an additional $18 million available upon achievement of clinical and corporate milestones. "This financing comes at a critical inflection point for Turn as we approach the mid-
- SECTurn Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure8-K - Turn Therapeutics Inc. (0002023016) (Filer)
- PRTurn Therapeutics Appoints Dr. Robert Redfield as Senior Advisor of Health Policy and Regulatory AffairsNationally recognized public health leader and former Director of the CDC to provide strategic guidance on GX-03 development, the Company's lead investigational therapy Turn Therapeutics, Inc. (NASDAQ:TTRX), a clinical-stage biotechnology company developing targeted inflammatory and immunology therapies for dermatologic conditions, today announced the appointment of Robert Redfield, M.D., as Senior Advisor of Health Policy and Regulatory Affairs. In this role, Dr. Redfield will provide strategic guidance on clinical development, public health implications, and regulatory positioning of the company's lead investigational therapy, GX-03, which is currently in Phase 2 clinical trials. This
- SECTurn Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure8-K - Turn Therapeutics Inc. (0002023016) (Filer)
- PRTurn Therapeutics to Present at Upcoming TD Cowen and Oppenheimer Healthcare ConferencesTurn Therapeutics Inc. (NASDAQ:TTRX), a clinical-stage biotechnology company developing targeted inflammatory and immunology therapies for dermatology, today announced that Brad Burnam, Chief Executive Officer, will present at the 46th Annual TD Cowen Healthcare Conference and the 36th Annual Oppenheimer Healthcare Life Sciences Conference. The Company will provide an update on its dermatology pipeline, including the status of the ongoing Phase 2 clinical trial evaluating GX-03, the company's lead investigational therapy for moderate-to-severe atopic dermatitis (eczema). Management will also participate in one-on-one meetings with institutional investors. Conference Participation: 36
- INSIDERDirector Dewhurst Martin William was granted 21,882 shares (SEC Form 4)4 - Turn Therapeutics Inc. (0002023016) (Issuer)
- INSIDERSEC Form 3 filed by new insider Dewhurst Martin William3 - Turn Therapeutics Inc. (0002023016) (Issuer)
- SECTurn Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure8-K - Turn Therapeutics Inc. (0002023016) (Filer)
- PRTurn Therapeutics Announces Corporate and Pipeline Updates and 2026 Outlook Ahead of the 44th Annual J.P. Morgan Healthcare ConferencePhase 2 trial of GX-03 for moderate-severe atopic dermatitis on track to complete both interim analysis and topline data in first half of 2026 Appointment of Martin Dewhurst, a 30+ years McKinsey & Company M&A veteran, strengthens Company board of directors Expansion of intranasal vaccine pipeline to include intranasal Influenza candidate that may stimulate systemic immunity via targeted intranasal exposure without adjuvants or potentially harmful additives Progress on commercial partnerships with expected revenue generation in 2026 in advanced wound care market Turn Therapeutics, Inc. (NASDAQ:TTRX), a clinical-stage biotechnology company developing targeted inflammatory and
- SECTurn Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure8-K - Turn Therapeutics Inc. (0002023016) (Filer)
- PRTurn Therapeutics Appoints Martin Dewhurst to its Board of DirectorsLOS ANGELES, Jan. 07, 2026 (GLOBE NEWSWIRE) -- Turn Therapeutics Inc. (NASDAQ:TTRX), a clinical-stage biotechnology company developing targeted inflammatory and immunology therapies for dermatology, advanced wound care, and infectious diseases, announced today the appointment of Mr. Martin Dewhurst to its Board of Directors. Mr. Dewhurst brings more than 30 years of global leadership experience in life sciences, with a particular focus on mergers and acquisitions. "Martin's appointment comes at a pivotal moment for Turn Therapeutics as we advance a disciplined, M&A-focused strategy to expand our pipeline and accelerate long-term value creation," said Bradley Burnam, Chief Executive Office
- ANALYSTD. Boral Capital initiated coverage on Turn Therapeutics with a new price targetD. Boral Capital initiated coverage of Turn Therapeutics with a rating of Buy and set a new price target of $8.00
- INSIDEROfficer Chaudhary Zuraiz bought $8,750 worth of shares (2,500 units at $3.50), increasing direct ownership by 25% to 12,500 units (SEC Form 4)4 - Turn Therapeutics Inc. (0002023016) (Issuer)
TTRX FAQ
5 questionsWhere does TTRX stock trade?
Turn Therapeutics Inc. (TTRX) is listed on NASDAQ.What sector and industry is TTRX in?
Turn Therapeutics Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.What are analysts saying about TTRX?
Turn Therapeutics Inc. has had 1 recent analyst action on file. The most recent action was from D. Boral Capital: Buy with a $800.00 price target on 2025-12-29. Recent price targets cluster around $800.00.What companies are similar to TTRX?
Notable peers in the same industry include LLY (Eli Lilly and Company), AZN (AstraZeneca PLC), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), NVS (Novartis AG). Compare TTRX side-by-side with any of them on Quantisnow.How can I track TTRX on Quantisnow?
Quantisnow aggregates Turn Therapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow TTRX to receive live email and push alerts on every new disclosure.